1
|
Manzar GS, Rafei H, Kumar B, Shanley M, Acharya S, Liu B, Xu A, Wang XA, Islam S, Kaplan M, Basar R, Uprety N, Shrestha R, Garza LM, Li Y, Banerjee PP, Spiotto MT, Dabaja B, Rezvani K, Daher M. Radiation Therapy Sensitizes Head-and-Neck Cancer Cells to Killing by Chimeric Antigen Receptor (CAR)-NK Cells Targeting CD70. Int J Radiat Oncol Biol Phys 2023; 117:S167-S168. [PMID: 37784417 DOI: 10.1016/j.ijrobp.2023.06.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) CAR-T cell therapy is limited by toxicity, high cost, logistical manufacturing issues in the autologous setting and risk of GVHD in the allogeneic setting. Substitution of T cells with NK cells opens the possibility for an allogeneic off-the-shelf product with a better safety profile. However, the inadequate efficacy of CAR-NK cells against solid tumors can be extrapolated from experience with CAR-T cells. There is limited but promising preclinical evidence that radiation therapy (RT) enhances CAR-T cell tumoricidal activity against solid tumors. However, there is no data examining the potential synergy between RT and CAR-NK cell therapy. MATERIALS/METHODS We engineered CAR-NK cells with CD27 receptor as extracellular domain to target its natural ligand CD70, which is overexpressed in head-and-neck cancers (HNSCC). CAR-NK cell killing was assessed real-time through xCELLigence cytotoxicity assays. CD70+ OQ01 human HNSCCs were used for most experiments. FaDu is a CD70- HNSCC (negative ctrl). UMRC3 is a CD70+ kidney cancer cell line (positive ctrl). CD70 expression pre- and post-RT was assessed by flow cytometry and Western blot. Ionizing RT was compared at 5 doses: 0, 1.75, 3.5, 7, and 14 Gy. A single dose of 3.5 Gy was used for most experiments. Post-radiation effects were generally assessed at 3 days or 9 days post-RT. Intracellular staining was used to assess NK cell expression of IFN-γ, CD107a, and TNF-α by flow cytometry. CD27/CD70 interaction blockade was through α-CD27 pre-treatment of CAR-NK cells. RESULTS OQ01 HNSCCs heterogeneously express CD70 and are killed by CD70 CAR-NK cells in vitro. Pre-conditioning low-dose RT of 3.5 Gy applied to OQ01 HNSCCs 3 days prior to coculture with NK cells enhances CD70 CAR-NK cell killing, with ∼30% increased cytotoxicity against the tumor cells. Low-dose RT by itself did not induce acute cytolysis. As a possible mechanism for the increased sensitivity of irradiated OQ01 cells to CD70 CAR-NK cells, we found that RT enhances CD70 expression among HNSCCs in a dose-dependent manner. There was no increase in NK cell expression of IFN-γ, CD107a, and TNF-α with exposure to irradiated target cells. CD27/CD70 blockade does not solely abrogate RT-induced sensitization toward CAR-NK cell killing. Despite RT induction of transient increased expression of CD70, which normalizes by 9 days post-RT, there is persistent increase in RT-synergized target cell killing even at this later timepoint. Thus, altogether, RT sensitizes CD70-expressing HNSCC cells to CAR-NK cell killing in vitro. CONCLUSION This work represents the first preclinical study to identify the synergy of RT and CAR-NK cell therapy in solid tumors and is the first demonstration of CAR-NK cell activity against human HNSCCs. We show significantly enhanced potency of CAR-NK cells against irradiated tumor cells in vitro. Collectively, this research will be vital to guide efforts expanding into other target antigens and tumor types.
Collapse
Affiliation(s)
- G S Manzar
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Rafei
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - B Kumar
- Department of Radiation Oncology City of Hope, Duarte, CA
| | - M Shanley
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Acharya
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - B Liu
- MD Anderson Cancer Center, Houston, TX
| | - A Xu
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - X A Wang
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Islam
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - M Kaplan
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Basar
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - N Uprety
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Shrestha
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Melo Garza
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Y Li
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - P P Banerjee
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - M T Spiotto
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - B Dabaja
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - K Rezvani
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - M Daher
- The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
2
|
Shah NN, Parta M, Baird K, Rafei H, Cole K, Holland SM, Hickstein DD. Monozygotic twins with GATA2 deficiency: same haploidentical-related donor, different severity of GvHD. Bone Marrow Transplant 2017; 52:1580-1582. [PMID: 28825694 DOI: 10.1038/bmt.2017.180] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- N N Shah
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - M Parta
- Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, MD, USA
| | - K Baird
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.,Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
| | - H Rafei
- George Washington School of Medicine and Health Sciences, Washington, DC, USA
| | - K Cole
- Office of the Clinical Director, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - S M Holland
- Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - D D Hickstein
- Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
3
|
Tfayli A, Rafei H, Khalil M, Mina A, Fakhreddin N, Mahfouz R, Farhat F, Rabee H, Hamouri S, Dbouk H, Salem Z, Saghir N, Shamseddine A, Bitar N, Mougharbil A, Makarem J, Daw W. 211 Screening for the prevalence of EGFR and ALK mutations in lung adenocarcinoma patients in the levant area, a prospective analysis. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30099-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
4
|
Tfayli A, Khalil M, Mina A, Rafei H, Fakhreddin N, Mahfouz R, Farhat F, Hamouri S, Dbouk H, Zaatari G. Screening for the Prevalence of EGFR and Alk Mutations in Lung Adenocarcinoma Patients in the Levant Area, a Prospective Analysis. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv043.05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|